Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
20
EVO Quote, Financials, Valuation and Earnings
Last price:
$3.0900
Seasonality move
:
5689.93%
Day range:
$3.0800 - $3.1300
52-week range:
$2.8400 - $4.8000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.31x
P/B ratio:
1.16x
Volume:
53.9K
Avg. volume:
198.3K
1-year change:
-25.96%
Market cap:
$1.1B
Revenue:
$862.1M
EPS (TTM):
-$0.50
Analysts' Opinion
-
Consensus RatingEvotec SE has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.4436, Evotec SE has an estimated upside of 77.41% from its current price of $3.0800.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.0051 representing 100% downside risk from its current price of $3.0800.
Fair Value
-
According to the consensus of 1 analyst, Evotec SE has 77.41% upside to fair value with a price target of $5.4436 per share.
EVO vs. S&P 500
-
Over the past 5 trading days, Evotec SE has underperformed the S&P 500 by -0.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Evotec SE does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evotec SE revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Evotec SE reported revenues of $191.5M.
Earnings Growth
-
Evotec SE earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Evotec SE reported earnings per share of -$0.14.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
1.31x
EV / EBIT:
--
EV / Revenue:
1.67x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-13.37x
Price / Operating cash flow:
100.09x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$87.5M
Return On Assets:
-8.33%
Net Income Margin (TTM):
-21.21%
Return On Equity:
-17.7%
Return On Invested Capital:
-11.62%
Operating Margin:
-31.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $819.4M | $842.2M | $832.2M | $203.1M | $191.5M | |
| Gross Profit | $204.3M | $115.3M | $87.5M | $20.1M | -$72.4K | |
| Operating Income | -$51M | -$146.7M | -$153.8M | -$43.9M | -$59.7M | |
| EBITDA | -$67.8M | -$207.7M | -- | -- | -$30.1M | |
| Diluted EPS | -$0.38 | -$0.52 | -$0.50 | -$0.12 | -$0.14 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $728.2M | $1.1B | $994.4M | $779.1M | $931.9M | |
| Total Assets | $2B | $2.2B | $2.4B | $2.2B | $2.1B | |
| Current Liabilities | $294.1M | $333.9M | $459.5M | $372.3M | $440M | |
| Total Liabilities | $898.4M | $1B | $1.2B | $1.1B | $1.1B | |
| Total Equity | $1.2B | $1.2B | $1.2B | $1.1B | $940.2M | |
| Total Debt | $539.6M | $481.9M | $470.6M | $464.9M | $455.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$42.6M | -$330.1K | $45.2M | -$75.3M | |
| Cash From Investing | -- | -$138.5M | -$46.7M | -$28.8M | -$12.1M | |
| Cash From Financing | -- | -$105.3M | -$16.4M | -$7M | -$11.6M | |
| Free Cash Flow | -- | -$232M | -$103.6M | $14.2M | -$101.3M | |
EVO
Sector
Market Cap
$1.1B
$28.1M
Price % of 52-Week High
64.17%
50%
Dividend Yield
0%
0%
Shareholder Yield
-0.98%
-1.54%
1-Year Price Total Return
-25.96%
-17.67%
Beta (5-Year)
1.783
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.0838
200-day SMA
Sell
Level
$3.7031
Bollinger Bands (100)
Sell
Level
3.1074 - 3.8674
Chaikin Money Flow
Sell
Level
-60.8M
20-day SMA
Buy
Level
$3.0533
Relative Strength Index (RSI14)
Sell
Level
47.4301
ADX Line
Sell
Level
16.8977
Williams %R
Neutral
Level
-32.2581
50-day SMA
Sell
Level
$3.2946
MACD (12, 26)
Sell
Level
-0.0368
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
18.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.6728)
Sell
CA Score
(Annual)
Level (-0.7606)
Sell
Beneish M-Score
(Annual)
Level (-1.8236)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (0.469)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Stock Forecast FAQ
In the current month, EVO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EVO average analyst price target in the past 3 months is $5.4436.
-
Where Will Evotec SE Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evotec SE share price will rise to $5.4436 per share over the next 12 months.
-
What Do Analysts Say About Evotec SE?
Analysts are divided on their view about Evotec SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evotec SE is a Sell and believe this share price will drop from its current level to $3.0051.
-
What Is Evotec SE's Price Target?
The price target for Evotec SE over the next 1-year time period is forecast to be $5.4436 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evotec SE is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of EVO?
You can purchase shares of Evotec SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evotec SE shares.
-
What Is The Evotec SE Share Price Today?
Evotec SE was last trading at $3.0900 per share. This represents the most recent stock quote for Evotec SE. Yesterday, Evotec SE closed at $3.0800 per share.
-
How To Buy Evotec SE Stock Online?
In order to purchase Evotec SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get EVO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EVO
Sector
P/E ratio
--
23.88x
PEG ratio
-0.05x
-0.01x
P/B ratio
1.16x
1.81x
Price / LTM sales
1.31x
1.59x
Growth Metrics
EVO
Sector
Revenue growth
-5.71%
4.73%
Earnings growth
-15.39%
11.11%
Revenue (5-year growth)
11.53%
6.46%
Earnings forecast
-$0.01
-$0.18
Profitability
EVO
Sector
Profitability FY 2024
$71.2M
$3.6M
Return on invested capital
-11.62%
-31.77%
Return on assets
-8.33%
-28.18%
Return on equity
-17.7%
-37.47%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Apr
15
Estimated Next Earnings Date
Feb
4
Balance Sheet
EVO
Sector
Total cash
$278.8M
$26.3M
Short term investments
$94.1M
$26M
Total assets
$2.1B
$76.9M
Long term debt
$455.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
